Dr. Amy Paller discusses long-term safety and efficacy of ixekizumab in kids

The federal agency has assigned a target action date of January 31, 2026, for a decision.

Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.

Dr Jon E. Grant talks about the genetics, neurobiology, and cognitive processes of body-focused repetitive behaviors, which include trichotillomania, skin picking, and other behaviors.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.